ESGO 2019 congress, November 2-5, 2019 in Athens, Greece

ESGO Helga Salvesen Award in Translational Research

ESGO Helga Salvesen Awardee 2017

"It was a great honor to be recognized for the first ever Helga Salvesen Award for translational science at the ESGO 2017 Congress in Vienna, Austria.

The award carries a tremendous perceived value for me and was particularly inspiring, as I have known Helga personally and collaborated with her on several projects.

I remember Helga as a very dedicated and bright scientist, with a clear focus on translational science.

In the words of Helga: "true impact in research can only be accomplished when working together" and I couldn't agree more.

The award is a global mark and prestigious achievement and I hope that scientists receiving this honor will continue to improve the care of cancer patients in the spirit of Helga.

The Helga Salvesen Award is a one of a kind experience that I personally will never forget".

Tjalling Bosse, 2017 ESGO Translational Research Award winner

Tjalling Bosse Helga Salvesen Award Winner

Dr. T. Bosse is associate professor in the Dept of Pathology, at the Leiden University Medical Centre (LUMC) in the Netherlands, where he combines clinical work with his research within the Female Cancer Centre. He graduated medical school in 2008 at the Amsterdam Medical Centre and did his residency in pathology at the LUMC, followed by fellowships in gynaecological pathology and molecular pathology at Brigham and Womens Hospital in Boston. Dr. Bosse leads a translational research program focused on gynaecological cancers and is lead pathologist for the PORTEC trials.

He is also head of the quality control program for the clinical pathology laboratory. His team has recently published several studies on prognostic and predictive (molecular) biomarkers in endometrial cancer using a pragmatic clinically applicable approach. This work is the bases of a recently opened new trial, PORTEC4a, which is the first trial with molecular profiling as an integral component in gynaecologic cancer.